Only a small percent of patients eligible for assistance programs actually enroll, and Vivor is working with pharmaceutical companies to make the process of using patient assistance programs smoother, said Ian Manners, founder and CEO of Vivor.
Only a small percent of patients eligible for assistance programs actually enroll, and Vivor is working with pharmaceutical companies to make the process of using patient assistance programs smoother, said Ian Manners, founder and CEO of Vivor.
Transcript
What has participation by industry been in Vivor’s work? What do they feel they get out of it?
For industry, there’s always been a challenge of: I want to make sure I’m addressing out-of-pocket costs everywhere, but programs that have been available for years often go very underutilized. We often sometimes see for cancer patients, even though the eligibility rules are generous, over 90% of patients are eligible for assistance programs, in some cases fewer than 20% of patients are actually getting enrolled. The gap is huge, and we know that industry partners are very interested in increasing the utilization of programs so that they can help patients get on appropriate therapy.
We take in a very provider-first view—we make our software first for providers. They are our customer. We make our results completely comprehensive. There’s no pay-for-play at all. But, the way that we do work with industry partners is to make the enrollment process and the process of using an assistance program much smoother. We can work with pharma companies to make it a one-click enrollment using the information that’s already in our platform to get a patient set up and enrolled in an assistance program and then send back the results in real time. So, industry partners are very excited about that ability to improve the experience, and as a result get many more patients who need, deserve, financial assistance enrolled in their programs.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More